Victor Appay, PhD, explains how long-term ART slows immune aging, boosting HIV viral suppression and paving the way for ...

Doxy-PEP reshapes STI prevention, while congenital syphilis surges; experts urge scaling HIV and STI care infrastructure to ...

Today, the FDA issued draft guidance outlining a new regulatory pathway intended to help sponsors gain approval for highly ...

LIBERTY-AFRS-AIMS met its primary endpoint with a 50% reduction in CT sinus opacification at week 52 versus 10% with placebo (P<.0001).

Executive actions in 2025 produced a 90-day freeze and stop orders; waivers incompletely restored services, with notable gaps in PrEP access for nonpregnant, nonbreastfeeding individuals. New research ...

The increase in CRC-related mortality in younger adults is driven by screening delays and advanced-stage diagnoses, according to Jordan Karlitz, MD.

This poster reaffirms tirzepatide’s use in patients with HIV. As patients with HIV are diagnosed with diabetes at a higher rate, it is important that GLP-1 RAs are known to be safe and effective for ...

Development assistance for health has fallen back toward 2010 levels, disproportionately disrupting community-based HIV services and projecting increased infections and AIDS-related deaths.

Digital health record integration boosts medication safety, as OTC use rivals prescription use in chronic care management, found a new study led by Jody L. Green, PhD, Uprise Health.

Over the long term, Levin expects oral GLP-1s to gain favor over injectables. Most patients prefer pills to injections, and ...

The FDA has approved a label expansion for tirzepatide (Zepbound; Eli Lilly), allowing use of a 4-dose, single-patient-use KwikPen that delivers a full month of treatment in 1 device for chronic ...

Two large real-world analyses presented at ACTRIMS Forum 2026 shed new light on the multiple sclerosis (MS) care continuum, ...